NDLI: Pharmacological strategies for lowering LDL cholesterol: statins and beyond.

Please wait, while we are loading the content...

Year: 2017 Volume: 14

Year: 2016 Volume: 14

Year: 2016 Volume: 13

Year: 2015 Volume: 12

Year: 2014 Volume: 11

Year: 2013 Volume: 10

Year: 2012 Volume: 9

Year: 2011 Volume: 9

Year: 2011 Volume: 8

Year: 2011 Volume: 8 Issue: 12

Year: 2011 Volume: 8 Issue: 11

Year: 2011 Volume: 8 Issue: 10

Year: 2011 Volume: 8 Issue: 9

Year: 2011 Volume: 8 Issue: 8

Year: 2011 Volume: 8 Issue: 7

Year: 2011 Volume: 8 Issue: 6

Year: 2011 Volume: 8 Issue: 5

Novel HDL-directed pharmacotherapeutic strategies.

Pharmacological strategies for lowering LDL cholesterol: statins and beyond.

Lipid control in patients with diabetes mellitus.

Hypertension: meta-analyses: first-rank evidence or second-hand information?

Heart failure: wireless hemodynamic monitoringa new approach for managing HF.

Pharmacotherapy: inhibiting LV remodelingthe need for a targeted approach.

Heart failure: pentraxin 3a marker of diastolic dysfunction and HF?

Arrhythmias: a 'Schwartz score' for short QT syndrome.

Innate immune signaling in cardiac ischemia.

Diabetes: which DES is the safest?

Interventional cardiology: cardiac device lead extraction-similar outcomes in the OR and EP laboratory.

Risk factors: little need to incorporate obesity measures in calculations of cardiovascular disease risk.

Cardiac resuscitation: short training videos for hands-only CPR improve bystander responses in out-of-hospital cardiac arrest scenarios.

Device therapy: avoid apical lead position in CRT.

Hypertension: new meta-analysis shows no cancer risk with angiotensin-receptor blockers.

Arrhythmias: RAAS inhibition in atrial fibrillation-one strike, but not out?

Diabetes: olmesartan slows microalbuminuria.

Year: 2011 Volume: 8 Issue: 4

Year: 2011 Volume: 8 Issue: 3

Year: 2011 Volume: 8 Issue: 2

Year: 2011 Volume: 8 Issue: 1

Year: 2010 Volume: 7

Year: 2009 Volume: 6

Pharmacological strategies for lowering LDL cholesterol: statins and beyond.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Brautbar, Ariel Ballantyne, Christie M.
Description	Country affiliation: United States Author Affiliation: Brautbar A ( Section of Cardiovascular Research, Department of Medicine, Baylor College of Medicine, Methodist DeBakey Heart and Vascular Center, 6565 Fannin, M.S. A-601, Houston, TX 77030, USA.)
Abstract	A continuous, graded relationship exists between LDL cholesterol (LDL-C) levels and risk of cardiovascular disease (CVD). This finding has been confirmed at progressively lower levels of LDL-C by results from clinical trials of therapies, particularly high-potency statins, which provide increasingly greater reductions in LDL-C levels. On the basis of this clinical trial evidence, progressively lower LDL-C goals for increasing numbers of patients, stratified by absolute CVD risk, have been recommended in guidelines for cholesterol management and CVD prevention. Some notable exceptions have been made, however, such as patients with end-stage renal disease or heart failure. To achieve low LDL-C goals, statins are first-line pharmacological therapy and can be combined with other agents to provide additional reductions in LDL-C levels as well as improvements in other lipoprotein fractions. Investigational agents that reduce LDL-C levels by other mechanisms are under development and could provide additional therapeutic strategies to achieve optimal LDL-C levels. These agents could be particularly appropriate for patients with severely elevated LDL-C levels, such as those with genetic dyslipidemia, for whom maximal drug therapy is insufficient to reduce LDL-C concentrations to recommended levels.
File Format	HTM / HTML
ISSN	17595002
Issue Number	5
Volume Number	8
e-ISSN	17595010
Journal	Nature Reviews Cardiology
Language	English
Publisher	Nature Publishing Group
Publisher Date	2011-05-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Cardiology Cardiovascular Diseases Prevention & Control Cholesterol, Ldl Blood Dyslipidemias Drug Therapy Hydroxymethylglutaryl-coa Reductase Inhibitors Therapeutic Use Hypolipidemic Agents Animals Biological Markers Etiology Drug Therapy, Combination Complications Humans Practice Guidelines As Topic Risk Assessment Risk Factors Treatment Outcome Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Cardiology and Cardiovascular Medicine

Central Library (ISO-9001:2015 Certified)
Indian Institute of Technology Kharagpur
Kharagpur, West Bengal, India | PIN - 721302

See location in the Map
03222 282435
Mail: support@ndl.gov.in

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in